Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, and Cancer Genomics and Diagnostics.
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
Figure 3 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Supplementary Tables S1 - S5 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Figure 6 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Figure 5 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Figure 4 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Figure 2 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Figure 1 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Supplementary Fig. S1 - S12 from Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody Blockade
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma.
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
The potential clinical utility of Whole Genome Sequencing for patients with cancer: evaluation of a regional implementation of the 100,000 Genomes Project.
Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.
A clinical trial assessing the addition of continuous ketogenic diet therapy to standard chemotherapy and immunotherapy treatment for patients with advanced squamous cell lung cancer
Lung adenocarcinoma promotion by air pollutants.
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
The evolution of lung cancer and impact of subclonal selection in TRACERx
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.
The evolution of lung cancer and impact of subclonal selection in TRACERx.
The evolution of non-small cell lung cancer metastases in TRACERx
Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
The evolution of non-small cell lung cancer metastases in TRACERx.
Genomic-transcriptomic evolution in lung cancer and metastasis.
Body composition and lung cancer-associated cachexia in TRACERx
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.